Back to the full story2 sources · Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks◆ Analytics
Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks
Deterministic text analytics computed across all 2 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
astrazenecabristolsquibbmyersdealdrugmakerlargestsourcemergercreate
Top phrases
bristol myers squibbbristol myersmyers squibbmerger talks
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- AstraZeneca · 2 sources
- Bristol Myers Squibb · 2 sources
Unique to one source
- Senior · Quartz
- Reuters · Quartz
- Proposed · The Guardian US
- More · The Guardian US
- Britain’s · The Guardian US
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
No sentence appeared in more than one source.
Appears once
- "A source close to the matter told Reuters there is "no deal" and there "never was a deal to be done" between the two drugmakers A source close to the matter told Reuters there is "no deal" and there "never was a deal to be done" between the two drugmakers" · Quartz
- "AstraZeneca, run by Pascal Soriot, its longtime chief executive, had been worth nearly £196bn before the news broke." · The Guardian US
- "BMS, headquartered in Princeton, New Jersey, and known for its cancer treatments, was worth $133..." · The Guardian US